News

Dr. Yong-Su Jin's research on Intracellular Hydroxyproline Imprinting explores collagen synthesis and degradation in resolving bleomycin-induced pulmonary fibrosis. Using CHPs, the study challenges conventional theories, suggesting that fibrosis can self-resolve, contrary to high hydroxyproline levels imply.

A great new article from a collaboration between Dr. Jeff Weiss's lab and our founder, Dr. Michael Yu's lab at the University of Utah. The new Acta Biomaterialia paper explores at what point collagen denaturation occurs in tendons under mechanical strain and how tendon type influences the mechanism of failure. Researchers evaluated functionally distinct...

Discover Dr. Yang Li's ACS Nano study on Collagen Health Peptides (CHPs) with Cy5 tagging for precise assessment of spinal collagen. Unveil CHPs' unique sensitivity, surpassing traditional methods. Explore the future of spinal health applications.

Innovation partnership builds on 3Helix’s breakthrough developments in collagen-hybridizing peptide (CHP) technology. BASF to exclusively commercialize 3Helix’s technology to introduce CHP innovation to the personal care market. BASF will join 3Helix Board of Directors. Advancing BASF Care Chemicals’ Care 360° – Solutions for Sustainable Life Ludwigshafen, Germany and Salt Lake City, Utah, USA, November...